Ultraschall Med
DOI: 10.1055/a-2679-1034
Guidelines & Recommendations

Update zu: Ersttrimester Diagnostik und Therapie @ 11–13+6 Schwangerschaftswochen

Amendment zur Leitlinie der DEGUM, ÖGUM, SGUMGG, DGGG, ÖGG, Gynecologie Suisse, DGPM, DGPGM, BVF, ACHSE (AWMF S2e LL 085-002 1.1.2024) (https://register.awmf.org/de/leitlinien/detail/085-002) Article in several languages: English | deutsch
Constantin S. von Kaisenberg
1   Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany
,
Peter Kozlowski
2   Praenatal-Medicine and Genetics Düsseldorf, MVZ Amedes für Praenatal-Medizin und Genetik GmbH, Düsseldorf, Germany
,
Karl O. Kagan
3   Obstetrics and gynaecology, University Hospital Tübingen, Tübingen, Germany
,
Markus Hoopmann
3   Obstetrics and gynaecology, University Hospital Tübingen, Tübingen, Germany
,
Kai-Sven Heling
4   Praxis, Prenatal Diagnosis and Human Genetics, Berlin, Germany
,
Rabih Chaoui
4   Praxis, Prenatal Diagnosis and Human Genetics, Berlin, Germany
,
Philipp Klaritsch
5   Department of Obstetrics and Gynecology, Medical University Graz, Graz, Austria
,
Barbara Pertl
6   Privatklinik Graz Ragnitz, Pränatalzentrum Graz Ragnitz, Graz, Austria
,
Tilo Burkhardt
7   Department of Obstetrics, University Hospital Zürich, Zürich, Switzerland
,
Sevgi Tercanli
8   Praxis, Ultraschall Freie Strasse, Basel, Switzerland
,
Jochen Frenzel
9   Praxis, Praxis, Saarbrücken, Germany
,
Christine Mundlos
10   ACHSE Wissensnetzwerk, ACHSE, Berlin, Germany
› Author Affiliations
Preview

1. Introduction: First-trimester screening for abnormal glucose metabolism

A summary of the guideline (LL) was published in 2 parts in “Ultraschall in der Medizin” [1] [2]. The full version has been published at https://register.awmf.org/de/leitlinien/detail/085-002. Amendment 1.3 to Chapter 11 of the full version, published on 20 June 2025, replaces the previous version of Chapter 11 of the guideline.

Amendment 1.3 had become necessary because a Trilogy in “Lancet” [3] [4] [5] had published evidence requesting a change in paradigm of screening and prevention for GDM from 24–28 weeks of gestation to the 11–13+ 6 weeks of gestation.

The rationale for an amendment for chapter 11 is new evidence that early screening at 11–13+ 6 weeks and early intervention in high risk groups halves macrosomia and respiratory distress in neonates. There are additional non-significant positive effects.

The guideline groups AWMF 085–002 S2e LL “First trimester diagnosis and therapy at the 11–13+ 6 weeks of pregnancy” and AWMF 057–008 S3 LL “Gestational diabetes mellitus (GDM): diagnosis, therapy and follow-up” have independently adopted recommendations on GDM screening in the first trimester, subsequently harmonizing them for both guidelines. The 2 groups also refer to each otherʼs guidelines.

The following information is based on the short version of Amendment 1.3.

For the full version both in English and German, please go to the link above on the AWMF website.



Publication History

Article published online:
09 September 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany